NeuroMetrix, Inc. (NURO) announced yesterday that its wearable neurostimulation technology device Quell has received Breakthrough Designation from the U.S. FDA for treating fibromyalgia in adults. Shares skyrocketed 208% on the news, closing at $10.04 on July 20. (See NeuroMetrix stock charts on TipRanks) Fibromyalgia causes widespread body pain, sleep problems, fatigue, and often emotional and mental distress. Scientific studies point to abnormalities in the way the brain processes normal sensations and pain. About 2% - 6% of the U.S. population aged 30 - 50 suffer from this condition.
https://www.tipranks.com/news/neurometrixs-quell-receives-device-designation-from-fda-shares-skyrocket-208?utm_source=advfn.com&utm_medium=referral
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more NeuroMetrix Charts.
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more NeuroMetrix Charts.